Comprehensive Landscape of Post-Translational Modification Alterations in Nephrolithiasis Revealing Activation of Multiple Cell Death Pathways
Journal of Proteome Research · 2026
DOI: 10.1021/acs.jproteome.6c00230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Proteome Research, 2026. Verfasst von Yining Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shandong Provincial Third Hospital, Shandong University, Jinan250031, Shandong, China. Hauptthemen laut MEDLINE: Nephrolithiasis, Protein Processing, Post-Translational. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shandong Provincial Third Hospital Research Fund.
Abstract (Originalsprache)
Nephrolithiasis is a common urinary disorder characterized by high prevalence and recurrence, but the molecular mechanisms underlying calcium oxalate (CaOx)-crystal-induced renal injury remain incompletely understood. We applied integrated proteomic, phosphoproteomic, acetylomic, and lactylomic analyses to kidney tissues from a mouse model of CaOx nephrolithiasis followed by bioinformatic analysis and experimental validation. We identified 658 differentially expressed proteins, 735 differential phosphorylation sites, 335 differential acetylation sites, and 113 differential lactylation sites. Functional enrichment indicated immune activation, fibrotic remodeling, and alterations in PI3K-Akt, NOD-like receptor, p53, and Toll-like receptor signaling together with changes in fatty acid degradation, the tricarboxylic acid cycle, and glycolysis. Kinase activity prediction suggested the relative activation of multiple cyclin-dependent kinases. Proteins associated with ferroptosis, autophagy, necroptosis, and pyroptosis, including ACSL4, BNIP3, RIPK3, and GSDMD, showed coordinated abundance and modification changes. Several candidate sites, including MTOR_S1849, GCLM_K94, GCLM_S59, and GSS_K172, were also dysregulated. These data provide a multiomics resource for CaOx nephrolithiasis and identify candidate PTM events and regulatory pathways for future mechanistic validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Shandong Provincial Third Hospital, Shandong University, Jinan250031, Shandong, China.
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan250012, Shandong, China.
- School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao266109, Shandong, China.
- Department of Urology, The Second Qilu Hospital of Shandong University, Jinan250033, Shandong, China.
- Department of Urology, Shandong Provincial Third Hospital, Shandong University, Jinan250031, Shandong, China.
- Center for Translational Medicine Research, Shandong Provincial Third Hospital, Shandong University, Jinan250031, Shandong, China.
ORCID-Profile: Mengya Zhang, Xiaolu Zhang
Förderung
- Shandong Provincial Third Hospital Research Fund
Zitieren
APA
Dong, Y., Zhang, M., Xu, Y., Zhang, J., Wang, C., Zhang, X., & Ni, Y. (2026). Comprehensive Landscape of Post-Translational Modification Alterations in Nephrolithiasis Revealing Activation of Multiple Cell Death Pathways. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.6c00230
Vancouver
Dong Y, Zhang M, Xu Y, Zhang J, Wang C, Zhang X, et al. Comprehensive Landscape of Post-Translational Modification Alterations in Nephrolithiasis Revealing Activation of Multiple Cell Death Pathways. Journal of Proteome Research. 2026. doi:10.1021/acs.jproteome.6c00230
BibTeX
@article{Dong2026,
author = {Dong, Yining and Zhang, Mengya and Xu, Yang and Zhang, Jianchao and Wang, Changjuan and Zhang, Xiaolu and Ni, Yongliang},
title = {Comprehensive Landscape of Post-Translational Modification Alterations in Nephrolithiasis Revealing Activation of Multiple Cell Death Pathways},
journal = {Journal of Proteome Research},
year = {2026},
doi = {10.1021/acs.jproteome.6c00230}
}
EUVIMED